H2BFWT Inhibitors
Chemical inhibitors of H2BFWT act primarily by disrupting the deacetylation process of histones, which is a fundamental step in the regulation of chromatin structure and gene expression. Histone deacetylase inhibitors, such as Trichostatin A, Mocetinostat, Panobinostat, Vorinostat, Entinostat, Romidepsin, Belinostat, CUDC-101, Valproic acid, Quisinostat, Givinostat, and Chidamide, elevate the level of acetylation on histone tails, leading to a more open chromatin conformation. This state of chromatin can interfere with the normal function of H2BFWT, which is involved in the packaging of DNA into nucleosomes and the regulation of gene expression. The increased acetylation levels that result from the action of these inhibitors can obstruct H2BFWT's ability to properly condense chromatin, which is critical for the control of transcriptional processes.
By maintaining histones in a hyperacetylated state, these chemical inhibitors can impede the interaction between H2BFWT and other proteins as well as with DNA itself, leading to a compromised chromatin remodeling capability. For example, Trichostatin A and Vorinostat can result in a chromatin structure that is less conducive to compaction, a process vital for the transcriptional repression of genes. Romidepsin, a cyclic peptide, and Belinostat, a hydroxamate, similarly can lead to an accumulation of acetylated histones, thus affecting H2BFWT's role in chromatin dynamics. Additionally, compounds like CUDC-101, with its multi-targeted inhibitory action, can increase histone acetylation levels, and by this action, it can disrupt H2BFWT's functionality within chromatin. The consistent theme among these chemicals is their ability to alter the epigenetic landscape by modulating the acetylation status of histones, which in turn modulates the structural and regulatory roles of H2BFWT within the chromatin framework. This mechanism ensures that the activity of H2BFWT is functionally diminished.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. It can inhibit the deacetylation of histones, which can lead to a more condensed chromatin structure. As H2BFWT is a histone protein, maintaining high levels of acetylation on histones can interfere with its ability to properly package DNA, thus functionally inhibiting H2BFWT. | ||||||
Mocetinostat | 726169-73-9 | sc-364539 sc-364539B sc-364539A | 5 mg 10 mg 50 mg | $214.00 $247.00 $1463.00 | 2 | |
Mocetinostat functions similarly to Trichostatin A as a histone deacetylase inhibitor. By preventing deacetylation, it can disrupt the normal function of H2BFWT related to DNA packaging and transcriptional regulation, as histone acetylation is critical for the chromatin structure where H2BFWT operates. | ||||||
Panobinostat | 404950-80-7 | sc-208148 | 10 mg | $200.00 | 9 | |
As a potent histone deacetylase inhibitor, Panobinostat increases the acetylation level of histones, potentially altering the interaction between H2BFWT and DNA, thereby inhibiting the physiological role of H2BFWT in the chromatin remodeling process necessary for transcriptional activation and repression. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Vorinostat, another histone deacetylase inhibitor, can lead to hyperacetylation of histones, which would be expected to interfere with H2BFWT's ability to compact chromatin effectively and thus hinder its role in the regulation of gene expression. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
Entinostat is a benzamide histone deacetylase inhibitor that can cause hyperacetylated histones, thereby potentially disrupting the normal chromatin-related functions of H2BFWT, such as transcription regulation and DNA repair processes, through alterations in the chromatin structure. | ||||||
Romidepsin | 128517-07-7 | sc-364603 sc-364603A | 1 mg 5 mg | $218.00 $634.00 | 1 | |
Romidepsin, a cyclic peptide histone deacetylase inhibitor, can alter the chromatin structure by maintaining histones in an acetylated state, which could hinder the ability of H2BFWT to interact with DNA and proteins necessary for its function in chromatin remodeling and transcriptional regulation. | ||||||
Belinostat | 414864-00-9 | sc-269851 sc-269851A | 10 mg 100 mg | $156.00 $572.00 | ||
Belinostat is a hydroxamate histone deacetylase inhibitor that can lead to the accumulation of acetylated histones. This alteration can disrupt the normal function of H2BFWT in chromatin compaction and gene regulation due to changes in the chromatin landscape. | ||||||
Valproic Acid | 99-66-1 | sc-213144 | 10 g | $87.00 | 9 | |
Valproic acid, a short-chain fatty acid, acts as a histone deacetylase inhibitor. By increasing the acetylation of histones, Valproic acid can disrupt the chromatin-related activity of H2BFWT, thus inhibiting its normal function in chromatin dynamics and gene expression control. | ||||||
JNJ-26481585 | 875320-29-9 | sc-364515 sc-364515A | 5 mg 50 mg | $321.00 $1224.00 | ||
Quisinostat is a potent histone deacetylase inhibitor that can lead to high levels of histone acetylation, potentially affecting H2BFWT's ability to maintain chromatin structure and regulate gene expression due to the alteration in the chromatin architecture. | ||||||
ITF2357 | 732302-99-7 | sc-364513 sc-364513A | 5 mg 50 mg | $340.00 $1950.00 | ||
Givinostat is a histone deacetylase inhibitor that affects histone acetylation levels, which can lead to a change in chromatin structure and thereby inhibit the functional properties of H2BFWT in terms of nucleosome organization and gene expression modulation. | ||||||